Cargando…
MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor
BACKGROUND: Large brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative stereotactic radiosurgery (SRS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (Na-SRS) followed by surgery was reported, demonstrati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648164/ http://dx.doi.org/10.1093/noajnl/vdab159.099 |
_version_ | 1784610746875772928 |
---|---|
author | Mitsuya, Koichi Deguchi, Shoichi Muto, Manabu Yasui, Kazuaki Onoe, Tsuyoshi Ogawa, Hirofumi Hayashi, Kenji Asakura, Hirofumi Harada, Hideyuki Hayashi, Nakamasa |
author_facet | Mitsuya, Koichi Deguchi, Shoichi Muto, Manabu Yasui, Kazuaki Onoe, Tsuyoshi Ogawa, Hirofumi Hayashi, Kenji Asakura, Hirofumi Harada, Hideyuki Hayashi, Nakamasa |
author_sort | Mitsuya, Koichi |
collection | PubMed |
description | BACKGROUND: Large brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative stereotactic radiosurgery (SRS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (Na-SRS) followed by surgery was reported, demonstrating lower rates of postoperative leptomeningeal dissemination (LMD) and symptomatic radiation necrosis (RN). We treated with neoadjuvant fractionated stereotactic radiotherapy (Na-fSRT) followed by surgery for large brain metastasis with piecemeal resection. METHODS: Twelve patients received Na-fSRT followed by surgery between July 2019 and April 2021. Na-fSRT dose was based on lesion size and was standard dosing. Surgery generally followed within 7 days after radiotherapy. RESULTS: The mean age was 68 years (51–79). Sixteen men and five women. Mean follow-up period was 8.5 months (1–24.9). Primary were lung; 10 (NSCLC; 9, SCLC (recurrence); 1), esophagus; 3, colon; 2, melanoma; 2, kidney; 2 (recurrence1), uterus body; 1, and liver; 1. The median maximum tumor diameter was 3.6 cm (2.6–4.9). Median PTV, GTV volume were 21.7ml, 15.5ml, respectively. The median fSRT dose was 30Gy/5fr, and the median time from fSRT to surgery was 4 days (1–7). As preoperative adverse event, intracranial hypertension and partial seizure grade 2 (CTCAE ver.5) were occurred, but controlled with steroid and osmotic diuretics and anticonvulsant. Grade 3 and more adverse events were not occurred. Gross total removal was performed in 95.2%. Event cumulative incidence as follows: cavity local recurrence 4.8% (subtotal removal case); distant brain failure 33%; LMD 4.8%; and symptomatic RN 0%. The median intracranial progression free survival was 7 months, and median overall survival was 8.4 months. CONCLUSIONS: Na-fSRT followed by piecemeal resection is safety and feasible, and may have therapeutic value for deep large brain metastasis and eloquent lesion. Further prospective investigations in multi-institutional settings are warranted. |
format | Online Article Text |
id | pubmed-8648164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86481642021-12-07 MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor Mitsuya, Koichi Deguchi, Shoichi Muto, Manabu Yasui, Kazuaki Onoe, Tsuyoshi Ogawa, Hirofumi Hayashi, Kenji Asakura, Hirofumi Harada, Hideyuki Hayashi, Nakamasa Neurooncol Adv Supplement Abstracts BACKGROUND: Large brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative stereotactic radiosurgery (SRS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (Na-SRS) followed by surgery was reported, demonstrating lower rates of postoperative leptomeningeal dissemination (LMD) and symptomatic radiation necrosis (RN). We treated with neoadjuvant fractionated stereotactic radiotherapy (Na-fSRT) followed by surgery for large brain metastasis with piecemeal resection. METHODS: Twelve patients received Na-fSRT followed by surgery between July 2019 and April 2021. Na-fSRT dose was based on lesion size and was standard dosing. Surgery generally followed within 7 days after radiotherapy. RESULTS: The mean age was 68 years (51–79). Sixteen men and five women. Mean follow-up period was 8.5 months (1–24.9). Primary were lung; 10 (NSCLC; 9, SCLC (recurrence); 1), esophagus; 3, colon; 2, melanoma; 2, kidney; 2 (recurrence1), uterus body; 1, and liver; 1. The median maximum tumor diameter was 3.6 cm (2.6–4.9). Median PTV, GTV volume were 21.7ml, 15.5ml, respectively. The median fSRT dose was 30Gy/5fr, and the median time from fSRT to surgery was 4 days (1–7). As preoperative adverse event, intracranial hypertension and partial seizure grade 2 (CTCAE ver.5) were occurred, but controlled with steroid and osmotic diuretics and anticonvulsant. Grade 3 and more adverse events were not occurred. Gross total removal was performed in 95.2%. Event cumulative incidence as follows: cavity local recurrence 4.8% (subtotal removal case); distant brain failure 33%; LMD 4.8%; and symptomatic RN 0%. The median intracranial progression free survival was 7 months, and median overall survival was 8.4 months. CONCLUSIONS: Na-fSRT followed by piecemeal resection is safety and feasible, and may have therapeutic value for deep large brain metastasis and eloquent lesion. Further prospective investigations in multi-institutional settings are warranted. Oxford University Press 2021-12-06 /pmc/articles/PMC8648164/ http://dx.doi.org/10.1093/noajnl/vdab159.099 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Supplement Abstracts Mitsuya, Koichi Deguchi, Shoichi Muto, Manabu Yasui, Kazuaki Onoe, Tsuyoshi Ogawa, Hirofumi Hayashi, Kenji Asakura, Hirofumi Harada, Hideyuki Hayashi, Nakamasa MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor |
title | MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor |
title_full | MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor |
title_fullStr | MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor |
title_full_unstemmed | MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor |
title_short | MET-6 Neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor |
title_sort | met-6 neoadjuvant fractionated stereotactic radiotherapy followed by piecemeal resection for metastatic brain tumor |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648164/ http://dx.doi.org/10.1093/noajnl/vdab159.099 |
work_keys_str_mv | AT mitsuyakoichi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT deguchishoichi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT mutomanabu met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT yasuikazuaki met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT onoetsuyoshi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT ogawahirofumi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT hayashikenji met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT asakurahirofumi met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT haradahideyuki met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor AT hayashinakamasa met6neoadjuvantfractionatedstereotacticradiotherapyfollowedbypiecemealresectionformetastaticbraintumor |